Mylan N.V. has launched in the United States esomeprazole magnesium delayed-release capsules USP, 20 mg and 40 mg, which is the generic version of AstraZeneca’s Nexium. Mylan received final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated for the treatment of gastroesophageal reflux disease in adults and children ages 1 and older.

Esomeprazole magnesium delayed-release capsules USP, 20 mg and 40 mg, had US sales of approximately $5.2 billion for the 12 months ending June 30, 2015, according to IMS Health, and as reported by Mylan.

Source: Mylan